Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma

NCT01010880 is registered in ClinicalTrials.gov with Biokine Therapeutics Ltd as lead sponsor.

NCT NCT01010880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01010880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma
Lead sponsor
Biokine Therapeutics Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2008
Completion date
July 31, 2010
Enrollment
16 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma